Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort

CONCLUSIONS: Add-on therapy with belimumab led to durable renal response in patients with LN in a real-life setting.PMID:34600347 | DOI:10.1016/j.jaut.2021.102729

Source: Journal of Autoimmunity - October 2, 2021 Category: Allergy & Immunology Authors: Mariele Gatto Francesca Saccon Laura Andreoli Elena Bartoloni Francesco Benvenuti Alessandra Bortoluzzi Enrica Bozzolo Enrico Brunetta Valentina Canti Paolo Cardinaletti Fulvia Ceccarelli Francesco Ciccia Fabrizio Conti Ginevra De Marchi Amato de Paulis S Source Type: research